Exploring how fibrinogen contributes to blood clotting issues in severe COVID-19 cases
Investigating fibrinogen as a pathologic and targetable mediator of COVID-19-associated coagulopathy
['FUNDING_OTHER'] · EMORY UNIVERSITY · NIH-11062130
This study is looking at how a protein called fibrinogen, which helps with blood clotting, might cause problems for people with severe COVID-19, and it hopes to find new ways to help these patients feel better.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | EMORY UNIVERSITY (nih funded) |
| Locations | 1 site (ATLANTA, UNITED STATES) |
| Trial ID | NIH-11062130 on ClinicalTrials.gov |
What this research studies
This research investigates the role of fibrinogen, a protein involved in blood clotting, in the complications associated with severe COVID-19. It aims to understand how elevated fibrinogen levels lead to blood viscosity and contribute to vascular damage in critically ill patients. By examining the mechanisms behind COVID-19-associated coagulopathy, the study seeks to identify potential therapeutic interventions that could improve patient outcomes. The research will utilize mechanistic studies and therapeutic plasma exchange to address these issues.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals experiencing severe COVID-19 symptoms, particularly those with coagulopathy or related complications.
Not a fit: Patients with mild COVID-19 symptoms or those who have fully recovered from the virus may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients suffering from severe COVID-19 and its complications.
How similar studies have performed: Previous research has indicated that targeting fibrinogen and understanding its role in coagulopathy may lead to significant advancements in treating severe COVID-19 cases.
Where this research is happening
ATLANTA, UNITED STATES
- EMORY UNIVERSITY — ATLANTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MAIER, CHERYL — EMORY UNIVERSITY
- Study coordinator: MAIER, CHERYL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome, adverse sequelae of coronavirus disease, adverse sequelae of coronavirus disease 2019